Brokerage firms covering shares of NeoGenomics, Inc. (NASDAQ:NEO) have given the stock a “Buy” rating on a consensus basis.- Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.40 on the shares. - Based on a recent trade, the shares are hovering around $16.40 which, according to analysts, yield significant upside potential to the $19.88 consensus target price.

Investing in the stock market offers the potential for big returns. On the flip side, investors can also experience major losses when trading equities. Investors are typically trying their best to maximize returns while limiting losses. Figuring out the best way to do this is no easy proposition. There may be periods where everything seems to be working out, and the returns are rolling in. There may be other times when nothing seems to be going right, and the losses start to pile up. Nobody can predict with pinpoint certainty which way the market will shift in the future. Preparing the portfolio for multiple scenarios can help the investor stick it out when the waters get choppy. Having a properly diversified stock portfolio may help investors ride out the turbulence when it inevitably takes control of the market.

Wall Street firms hire hundreds- of analysts who provide recommendations on stocks.- Typically, these analysts look at a company’s fundamentals, building financial models from this information in order to project future trends, specifically future earnings.-

These projections are then used as a basis for providing -ldquo;buy-rdquo; or -ldquo;sell-rdquo; recommendations.- Many investors consider these recommendations very seriously, and often times whenever an analyst changes their outlook on a stock, the price change almost immediately.

Investors are usually trying to figure out the best strategy to use when tackling the equity market. Because there is no one perfect method for picking winning stocks, investors may have to try various techniques before they get it right. There are many different factors that can affect the financial health of a company, and this makes it hard to concoct a formula that works well across the board. Studying all the data can help with investing decisions, but it is typically more important to be focusing on the right information. Knowing exactly what data should be studied may only come by logging many hours of research.

Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will -ldquo;beat-rdquo; the artificially lowered estimate in order to get inexperienced investors to buy.


NeoGenomics, Inc. (NASDAQ:NEO)-rsquo;s shares may have a significant upside to the consensus target of- 19.88, but how has it been performing relative to the market?- The stock-rsquo;s price is 16.40 and their relative strength index (RSI) stands at 62.50.- RSI is a technical oscillator that shows price strength by comparing upward and downward movements.- It indicates oversold and overbought price levels for a stock. -

NeoGenomics, Inc. (NASDAQ:NEO) shares are moving- -1.32% trading at $16.40 today,

When doing stock research, there is plenty of easily measureable data regarding publically traded companies. There is also plenty of information that is not easily measured such as competitive advantage, quality of staff, and company reputation. Because there are forces such as the human element that come into play when selecting stocks, prices may not always move as expected. Even after crunching all the numbers and digging deep into a specific company, the stock’s performance still might not match expectations. Investors may realize that sometimes perception can be more powerful than reality. Human emotions can change very rapidly, and so can the prevailing market sentiment as well.

Full article